SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Condition:   Nasopharyngeal Carcinoma
Intervention:   Drug: SHR-1210
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting

https://ift.tt/2takPxf